Jason Napodano, CFA
Research analyst, medium-term horizon, biotech, small-cap

Investment In Nuvo Research Looks Like An Easy Call

On May 29, 2014, Nuvo Research (OTCPK:NRIFF) announced that a third party has received FDA approval to market and sell a topical diclofenac sodium 1.5% solution in the U.S. The product is a generic version of Pennsaid® 1.5%. Although this initially sounds like bad news for Nuvo Research, Mallinckrodt (NYSE:MNK), Nuvo's licensee of both Pennsaid® 1.5% and Pennsaid® 2%, has been actively transitioning patients and healthcare providers from Pennsaid®1.5% to Pennsaid® 2% during 2014. While the transition is not yet complete, we have been able to obtain weekly prescription data for the two products, with the data showing that Pennsaid® 2% prescriptions having recently overtaken Pennsaid® 1.5% prescriptions. We forecast this trend to continue, and thus...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details